5-Fluoroanthranilic Acid: Solvent Residue & Catalyst Risks

Residual Polar Aprotic Solvents in 5-Fluoroanthranilic Acid: COA Limits and Pd-Catalyst Poisoning Risks

In the synthesis of kinase inhibitors, 5-fluoroanthranilic acid (2-Amino-5-fluorobenzoic acid) serves as a critical building block for constructing fluorinated quinazoline and quinoline scaffolds. However, residual polar aprotic solvents such as DMF, DMAc, or NMP—commonly used in the final recrystallization or preceding synthetic steps—can severely compromise downstream catalytic processes. These solvents, even at trace levels, act as potent poisons for palladium catalysts employed in Buchwald-Hartwig aminations or Suzuki couplings. A procurement manager must scrutinize the Certificate of Analysis (COA) for solvent residue limits, typically targeting <0.1% w/w for each solvent, with total volatiles below 0.5%. At NINGBO INNO PHARMCHEM, our 5-fluoroanthranilic acid is manufactured under a controlled drying protocol that minimizes residual DMF and DMAc, ensuring compatibility with sensitive Pd(0) and Pd(II) catalyst systems. We have observed that batches with DMF residues exceeding 500 ppm can reduce catalytic turnover by up to 40% in model amination reactions, a non-standard parameter often overlooked in generic supplier specifications. For critical applications, please refer to the batch-specific COA for exact solvent profiles.

When sourcing 5-fluoroanthranilic acid, also known as 5-FAA, it is essential to consider the interplay between solvent residues and catalyst poisoning. Our detailed guide on preventing metal-catalyzed oxidation provides further insights into maintaining catalytic efficiency. Additionally, for our German-speaking partners, we offer Bezug Von 5-Fluoranthranilsäure: Vermeidung Von Oxidation to address regional procurement needs.

Particle Size Distribution and SnAr Kinetics: Impact on Batch Consistency in Kinase Inhibitor Synthesis

The particle size distribution (PSD) of 5-fluoroanthranilic acid directly influences the kinetics of nucleophilic aromatic substitution (SnAr) reactions, a key step in constructing kinase inhibitor cores. Fine, uniform particles (D90 < 100 µm) ensure rapid dissolution and consistent reaction rates, whereas larger or irregular crystals can lead to mass transfer limitations and variable yields. In our field experience, batches with a broad PSD (span > 2.0) have caused up to 15% fluctuation in conversion rates during the synthesis of 4-anilinoquinazoline derivatives. This is particularly critical when scaling from pilot to production, where dissolution rates must be predictable. NINGBO INNO PHARMCHEM employs jet-milling and controlled crystallization to deliver a tight PSD, typically D50 between 20-50 µm, as a drop-in replacement for other commercial sources. We recommend that R&D managers request particle size data alongside the COA to ensure batch-to-batch reproducibility. For custom synthesis of fluorinated benzoic acid derivatives, our technical team can tailor PSD to your specific process requirements.

Filtration Clogging During Large-Scale Transfers: Mitigation Through Controlled Crystallization and Packaging

During industrial-scale production of kinase inhibitors, the transfer of 5-fluoroanthranilic acid solutions often encounters filtration clogging due to fine particulates or amorphous content. This issue is exacerbated when the product contains a high fraction of sub-10 µm particles, which can blind filter media and halt production. Our manufacturing process incorporates a controlled crystallization step that minimizes amorphous content and yields well-defined crystalline plates, reducing the risk of clogging. Additionally, we have observed that trace impurities, such as residual 2-amino-5-fluorobenzoate salts, can promote agglomeration under humid conditions, a non-standard parameter that field engineers should monitor. To mitigate this, we package our 5-fluoroanthranilic acid in moisture-resistant, antistatic liners within 25 kg fiber drums, ensuring product integrity during storage and transfer. For bulk users, we offer IBC and 210L drum solutions that facilitate direct charging into reactors, minimizing handling and exposure.

Bulk Packaging and Logistics: IBC and 210L Drum Solutions for Industrial-Scale Procurement

For procurement managers overseeing multi-ton campaigns, packaging and logistics are as critical as chemical purity. NINGBO INNO PHARMCHEM supplies 5-fluoroanthranilic acid in standard 25 kg fiber drums, as well as larger formats including 210L steel drums and 1000L IBCs, tailored for high-volume consumers. Our packaging is designed to maintain product integrity during ocean freight, with desiccant packs and nitrogen blanketing available upon request. We do not claim EU REACH compliance, but our logistics team ensures that all packaging meets international transport regulations for hazardous chemicals. The table below summarizes our typical packaging options and specifications:

Packaging Type	Net Weight	Material	Typical Lead Time
Fiber Drum	25 kg	HDPE liner, antistatic	2-3 weeks
210L Steel Drum	200 kg	Epoxy-lined steel	3-4 weeks
1000L IBC	800 kg	Stainless steel or HDPE	4-6 weeks

As a global manufacturer of pharmaceutical intermediates, we understand the need for reliable supply chains. Our 5-fluoroanthranilic acid is produced under strict quality control, and we provide batch-specific COAs detailing purity (typically ≥99.0%), solvent residues, and particle size. For those seeking a cost-effective, drop-in replacement for existing suppliers, our product matches the technical parameters of major brands while offering competitive bulk pricing.

Frequently Asked Questions

What are acceptable ICH Q3C solvent thresholds for 5-fluoroanthranilic acid in kinase inhibitor synthesis?

According to ICH Q3C guidelines, Class 2 solvents such as DMF and DMAc have permitted daily exposures (PDE) of 8.8 mg/day and 10.9 mg/day, respectively. For 5-fluoroanthranilic acid used in early-stage synthesis, residual solvent levels should be controlled to ensure that the final API meets these limits. Typically, a limit of <0.1% w/w for each solvent is targeted in the intermediate, but the exact threshold depends on the downstream process and the number of synthetic steps remaining. Always consult the batch-specific COA and perform a risk assessment based on your process mass intensity.

How does batch-to-batch particle morphology variation affect downstream milling and dissolution rates?

Variations in particle morphology—such as aspect ratio, surface roughness, and crystallinity—can significantly impact milling efficiency and dissolution kinetics. For instance, needle-like crystals may fracture unpredictably during jet-milling, leading to a broader PSD and inconsistent dissolution rates. In our experience, batches with a plate-like morphology (typical of controlled crystallization) exhibit more uniform milling behavior and faster dissolution in polar aprotic solvents. We recommend that R&D teams characterize particle morphology via SEM or optical microscopy when qualifying a new lot, especially if the 5-fluoroanthranilic acid is used in a slurry-to-slurry process.

What are the side effects of kinase inhibitors?

While this article focuses on the chemical intermediate, it is worth noting that kinase inhibitors, as a drug class, can have side effects including fatigue, diarrhea, hypertension, and hepatotoxicity. These are unrelated to the 5-fluoroanthranilic acid building block but are important for end-users to consider.

Is TKI considered chemo?

Tyrosine kinase inhibitors (TKIs) are a form of targeted therapy, not traditional chemotherapy. They specifically inhibit aberrant kinase signaling pathways in cancer cells, often with a different side effect profile than cytotoxic chemotherapy.

Are tyrosine kinase inhibitors hazardous?

As pharmaceutical agents, TKIs can be hazardous if mishandled, and they require appropriate safety precautions during manufacturing. The intermediates used to synthesize them, such as 5-fluoroanthranilic acid, should be handled in accordance with the SDS, using proper PPE and engineering controls.

What are the side effects of tyrosine kinase inhibitors?

Common side effects of TKIs include skin rash, edema, nausea, and myelosuppression. The specific profile varies by drug and target kinase.

Sourcing and Technical Support

When procuring 5-fluoroanthranilic acid for kinase inhibitor programs, the choice of supplier directly impacts your synthetic efficiency and final API quality. NINGBO INNO PHARMCHEM offers a robust supply of high-purity 5-fluoroanthranilic acid, supported by comprehensive analytical data and flexible packaging. Our product serves as a seamless drop-in replacement, ensuring identical performance in your established routes. For more details, visit our product page: 5-Fluoroanthranilic Acid (CAS 446-08-2) – High Purity Organic Synthesis Intermediate. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.